drugset / Trial / NCT04402008
Study of Poziotinib in Japanese Patients With NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 1/2, open-label, multicenter study to determine dose, tolerability, safety and efficacy of poziotinib in Japanese patients non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2020-06-23
- Primary completion
- 2023-02-15
- Completion
- 2023-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Poziotinib | Small molecule | 4 mg | Oral |
| Subject | Poziotinib | Small molecule | 6 mg | Oral |
| Subject | Poziotinib | Small molecule | 8 mg | Oral |
| Subject | Poziotinib | Small molecule | 12 mg | Oral |
| Subject | Poziotinib | Small molecule | 16 mg | Oral |